Whole-body FDG-PET Imaging Research Articles

Value of FDG PET for mediastinal lymph node staging in non-small cell lung cancer

To evaluate the diagnostic significance of FDG PET in preoperative mediastinal lymph node staging for NSCLC. Whole-body FDG PET imaging was performed in 70 patients with NSCLC. All patients received thoracic CT examination 2 weeks before PET scan or 1 week after PET scan, and then were given thoracotomy with hilar and mediastinal lymph nodes dissection. After intravenous administration of 18F-FDG (150μCi/kg), PET scan was performed in 3-7 bed positions with 2D acquisition and OSEM reconstruction. For quantitative evaluation, a region of interest (ROI) was placed over the mediastinal lymph node which had abnormal uptake of radiation activity, then the standardized uptake value (SUV) were calculated. If SUV≥2.5 or uptake activity was higher than the blood pool of mediastinal on the basis of visual inspection, it was considered to be positive. The sensitivity, specificity and accuracy of PET were 100%, 93% and 94%, respectively. The positive lymph nodes diagnosed by PET correctly corresponded to pathological results. PET changed the clinical staging of 12 patients. The sensitivity, specificity and accuracy of CT were 70%, 77% and 76%, respectively. PET is an effective modality for accurate mediastinal lymph node staging in patients with NSCLC. It is valuable for determining clinical treatment.

Rapid normalization of osseous FDG uptake following traumatic or surgical fractures.

It is known that following a traumatic fracture or surgical intervention, bone scintigraphy reveals positive results for an extended period of time, posing a challenge when evaluating patients for possible malignancy or superimposed osteomyelitis. Previous reports indicate that acute fractures can also result in increased fluorine-18 fluorodeoxyglucose (FDG) accumulation and therefore cause difficulties when patients are evaluated for other indications by FDG-PET. The purpose of this study was to assess the pattern and time course of abnormal FDG uptake following traumatic or surgical fracture. A total of 1,517 consecutive patients who underwent whole-body FDG-PET imaging were retrospectively studied. A history of fractures or orthopedic intervention was obtained from an interview prior to scanning. The FDG-PET results were compared with the results of other imaging studies, including bone scans, radiographs, CT, and MRI, as well as surgical pathology reports. Thirty-seven patients with a known date of traumatic or surgical fracture were identified. Among these, 14 had fractures or surgery within 3 months prior to FDG-PET, while 23 had fractures or surgical intervention greater than 3 months prior to FDG-PET. FDG-PET showed no abnormally increased uptake at the known fracture or surgical sites in 30 of these patients. Notably, in the 23 patients with fractures more than 3 months old, all but one showed no abnormally increased uptake. Furthermore, the positive FDG uptake in this exception was a result of complicating osteomyelitis. In the 14 patients with a history of fracture less than 3 months old, only six had abnormally increased FDG uptake. Following traumatic or surgical fractures, FDG uptake is expected to be normal within 3 months unless the process is complicated by infection or malignancy.

Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules.

Fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging has been used extensively to diagnose cancer with high rates of sensitivity and specificity. One of its applications is to distinguish benign from malignant pulmonary nodules. It is common to observe colonic uptake on whole-body FDG-PET images. Because patients with lung cancer also tend to be in the age group with the highest incidence of colon cancer, the authors tried to assess the efficacy of FDG-PET for detecting occult colon cancer in patients referred for the evaluation of lung nodules. The records of 500 consecutive patients referred for the evaluation of pulmonary nodules were reviewed retrospectively. Among the patients, 197 had no previous clinical or radiographic evidence of abnormalities in the gastrointestinal tract, and none had been found to have any cancer before undergoing an FDG-PET study. All colon lesions were verified either by histologic analysis or by clinical course. Among the 197 patients analyzed, 59 had diffuse colonic uptake in various segments of the colon. Seventeen of the patients had focal colonic uptake, five of which were proved to be colon cancer. The routine use of FDG PET to characterize lung lesions significantly increases the probability of detecting unexpected extrathoracic disease. In these patients, the incidental finding of colon cancer had an important effect on their treatment and may prove to be very cost-effective.

2-Deoxy-2-[F-18]Fluoro-D-Glucose Imaging with Positron Emission Tomography for Initial Staging of Hodgkin's Disease and Lymphoma

Purpose: To assess the accuracy of 2-Deoxy-2-[F-18] Fluoro-D-Glucose positron emission imaging (FDG-PET) for staging Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) compared to conventional staging (CS) and to evaluate the impact on patient management. Methods: Forty-five consecutive patients with lymphoma underwent whole-body FDG-PET imaging for initial staging. Discordant lesions were verified with biopsy or clinical follow-up. The impact on staging and management was reviewed retrospectively. Results: A total of 129 sites of disease were identified, and 88 of those were concordant. FDG-PET and conventional staging demonstrated 24 and 17 additional sites, respectively. FDG-PET correctly upstaged five patients and down-staged two patients (16% total), leading to a change in therapy in 6/45 (13%) patients. However, FDG-PET understaged three patients (7%), correctly staged by conventional staging modalities. Assuming that the addition of FDG-PET to conventional staging modalities is 100% accurate for staging lymphoma, the accuracy of FDG-PET alone was 91%, compared to 84% for conventional staging modalities. Conclusions: FDG-PET is a noninvasive and efficient imaging modality for staging patients with lymphoma and should be used in conjunction with conventional staging modalities, as they appear complementary. (Mol Imag Biol 2002;4:105–114)

9:—9:15: 3D Data Acquisition for Whole Body Images on the ECAT HR+

Purpose: Evaluation of 3D clinical whole-body FDG PET imaging using recent improvements in data correction and reconstruction methods.Methods: Phantom studies following the NEMA NU 2-2000 draft were performed to evaluate count loss and accuracy of attenuation and scatter correction algorithms. Phantom results were used to estimate 3D vs. 2D efficiency. For patient studies, an established 2D imaging protocol (9 min emission, 3 min transmission acquisition per bed position, commencing 60 min after injection of 15 mCi FDG) was used. This was followed by a 3D acquisition of the same duration, commencing approximately 110 min later, so that 3D acquisition was performed with approximately 50% lower patient activity than 2D. Images were compared in terms of anatomic structural definition and visible artifacts.The count loss study showed that in a dose range of 10-15 mCi, 3D produced an approximately two-fold increase in effective NEC compared to 2D. The phantom imaging study showed slightly improved target to background ratios for both hot and the cold “lesions” when using 3D imaging. In 5 patients studied so far, comparison of 2D and 3D studies demonstrated no systematic differences in image quality between the two methods.Conclusion: 3D whole-body imaging with improved image reconstruction may permit a two-fold reduction in emission acquisition time or injected dose, without decrease in image quality compared to standard 2D imaging techniques.

Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.

This study was done to determine the feasibility and potential utility of whole-body PET using the glucose analogue 2-[18F]fluoro-2-deoxy-D-glucose (FDG) for the detection of primary malignancies and metastatic lesions. This was a prospective, nonrandomized study of whole-body FDG-PET imaging carried out at a large university teaching hospital in Los Angeles, CA, U.S.A. The study group consisted of all patients referred for PET imaging (87) with a suspected diagnosis of primary or recurrent malignancy and who had eventual histological confirmation of their lesions. In the 87 patients, whole-body PET studies were positive (presence of focal FDG uptake relative to surrounding tissues uptake) in 61 of 70 patients (87%) with subsequent biopsy-confirmed primary or recurrent malignant lesions, including carcinomas of breast, lung, ovary, prostate, colon, urinary bladder, and gallbladder origin, as well as malignant melanoma, carcinoid, osteosarcoma, lymphoma, and spinal cord astrocytoma. The PET images revealed no focal hypermetabolism at the known site of tumor in patients with primary prostate carcinoma (two), microscopic ovarian carcinoma (two), breast carcinoma (one), low-grade carcinoid tumors (two), and one patient with recurrent microscopic osteogenic sarcoma. The PET studies detected the primary lesion in 15 of 17 patients with breast carcinoma and in 6 of 6 patients with primary lung carcinoma. Of the 17 patients with benign biopsies, 13 patients had FDG-PET studies without focal areas of uptake. Because of the high glycolytic rate of malignant tissue, the whole-body FDG-PET technique has promise in the detection of a wide variety of both primary and metastatic malignancies. The presence of FDG uptake in benign inflammatory conditions may limit the specificity of the technique. The sensitivity for the detection of malignant lesions was 87% and the positive predictive value was 94%. The whole-body FDG-PET method is promising both in determining the nature of a localized lesion and in defining the systemic extent of malignant disease.